SIDT1-AS1

Across TCGA pan-cancer cohorts, SIDT1-AS1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SIDT1-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where SIDT1-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SIDT1-AS1 is over-expressed in tumor, although a few such as LUSC and THCA show the opposite, repressed pattern.

BRCA, KIRC, and STAD are the cancer types where SIDT1-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SIDT1-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	II,III,IV	+0.330	.002	4	view →
KIRC	All	II,III,IV	+0.054	.012	4	view →
STAD	All	All	+0.345	.006	3	view →
LUSC	All	All	−0.102	.011	2	view →
THCA	Female	All	−0.072	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SIDT1-AS1–BRCA

Open the BRCA breakdown →